Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Inclusion Criteria: * healthy volunteers * BMI between 18.5 and 29.9 kg/m2 * weighing between 55 and 95 kg * willing to use reliable contraception * able to give fully informed written consent. Exclusion Criteria: * Pregnant or lactating woman, or sexually active woman of child-bearing potential not using highly effective contraception * clinically relevant abnormal medical history, surgery or concurrent medical condition; acute or chronic illness * clinically significant QT/QTc interval prolongation at Baseline * history of drug-induced or risk factors for Torsade de Pointes * any contraindication to moxifloxacin * severe adverse reaction to any drug or sensitivity to the trial medication or its components * significant food allergy; use of vitamins, herbal medicines, prescription or over-the-counter medication (with the exception of paracetamol \[acetaminophen\] and oral contraceptives for women) within 20 days or 6 half-lives before first dose of trial medication * participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 mL blood, within the 3 months before first dose of trial medication * drug or alcohol abuse; smoking of more than 5 cigarettes, 1 cigars or 1 pipes daily * regular consumption of more than 5 cups of caffeinated drinks per day * positive test for hepatitis A, B \& C, HIV * objection by a General Practitioner.